TCL Archive Move Starts To Strip Anticancer Drug Regulation From FDA After New Charges It Is Delaying INDs October 15, 1976
TCL Archive FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity. September 29, 2000
TCL Archive The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year April 20, 2012
TCL Archive In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial April 29, 1988